ClinicalTrials.gg
TerminatedNCT03515629Updated Nov 16, 2022Results posted

REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer

A Phase 3 interventional study of REGN2810/ipi and REGN2810/chemo/ipi in Non-small Cell Lung Cancer, sponsored by Regeneron Pharmaceuticals. Terminated at 3 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-11-16.

Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment

Why this study was terminated
Business decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
5
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung — 18 open to participants now, 22 under way, 3 of them phase 3. cemiplimab · Carcinoma, Non-Small-Cell Lung.

Enrollment
28th of 29
5 · median 61
Started
2018
with 3 others
Phase 3
5 of 29
2 open now
Registered
4th of 29
by date
Lead sponsor
7 of 29
Regeneron Pharmaceuticals

Among the 29 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung, this one is the 28th largest by enrollment, is one of 4 that started in 2018, is one of 5 in phase 3, and was the 4th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

18 of the 29 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 18 open studies →

About cemiplimab

cemiplimab: first FDA approval 2018 (LIBTAYO), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing cemiplimab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The primary objective of the study is to compare the progression-free survival (PFS) of REGN2810 (cemiplimab) plus ipilimumab combination therapy (hereinafter referred to as REGN2810/ipi) and REGN2810 plus 2 cycles only of platinum-based doublet chemotherapy plus ipilimumab combination therapy (hereinafter referred to as "REGN2810/chemo/ipi") with standard-of-care pembrolizumab monotherapy in the first-line treatment of patients with advanced squamous or non-squamous non-small cell lung cancer (NSCLC) whose tumors express programmed death ligand 1 (PD-L1) in ≥50% of tumor cells. The key secondary objectives of the study are to compare the overall survival (OS) of REGN2810/ipi and REGN2810/chemo/ipi with pembrolizumab monotherapy in the first-line treatment of patients with advanced squamous or non-squamous NSCLC whose tumors express PD-L1 in ≥50% of tumor cells and to compare the overall response rate (ORR) of REGN2810/ipi and REGN2810/chemo/ipi with pembrolizumab monotherapy in the first-line treatment of patients with advanced squamous or non-squamous NSCLC whose tumors express PD-L1 in ≥50% of tumor cells.

03

Conditions studied

  • Non-small Cell Lung Cancer

Keywords

  • Stage IIIB
  • Stage IV
  • Non-squamous NSCLC
  • Squamous NSCLC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Patients with or cytologically documented squamous or non-squamous NSCLC with stage IIIB or stage IV disease, who received no prior systemic treatment for recurrent or NSCLC
  2. Availability of an archival (≤5 months) or on-study obtained formalin-fixed, paraffin-embedded tumor tissue sample which has not previously been irradiated
  3. Expression of in ≥50% of tumor cells determined by the commercially available assay performed by the central laboratory
  4. At least 1 radiographically measureable lesion by computed tomography (CT) or magnetic resonance imaging (MRI) per 1.1 criteria. Target lesions may be located in a previously irradiated field if there is documented (radiographic) disease progression in that site
  5. (ECOG) performance status of ≤1
  6. Anticipated of at least 3 months

Key Exclusion Criteria:

  1. Patients who have never smoked, defined as smoking ≤100 cigarettes in a lifetime
  2. Active or untreated or spinal cord compression
  3. Patients with tumors tested positive for Epidermal growth factor receptor (EGFR) gene mutations, Anaplastic lymphoma kinase (ALK) gene translocations, or C-ros oncogene receptor tyrosine kinase(ROS1) fusions
  4. Encephalitis, meningitis, or uncontrolled seizures in the year prior to
  5. History of interstitial lung disease (eg, idiopathic pulmonary fibrosis or organizing pneumonia), of active, noninfectious pneumonitis that required immune-suppressive doses of to assist with management, or of pneumonitis within the last 5 years
  6. Ongoing or recent evidence of significant disease that required treatment with systemic treatments, which may suggest risk of immune-related treatment-emergent adverse events (irTEAEs)
  7. Previous treatment with idelalisib at any time (ZYDELIG®)
  8. Patients with a condition requiring corticosteroid therapy (>10 mg prednisone/day or equivalent) within 14 days of randomization

Note: Other protocol defined Inclusion/Exclusion criteria may apply

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Active comparator
    Pembrolizumab

    Pembrolizumab

    Drug: Pembrolizumab

  • Experimental
    REGN2810/ipi

    REGN2810/ipi

    Drug: REGN2810/ipi

  • Experimental
    REGN2810/chemo/ipi

    REGN2810/chemo/ipi

    Drug: REGN2810/chemo/ipi

Interventions

  • DrugREGN2810/ipi

    Drug page: Cemiplimab

    REGN2810 plus ipilimumab

    Also known as: cemiplimab

  • DrugREGN2810/chemo/ipi

    Drug page: Cemiplimab

    REGN2810 plus chemotherapy plus Ipilimumab

    Also known as: cemiplimab

  • Reference drug administered IV infusion

This study also gives Ipilimumab. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS) as Assessed by a Blinded Independent Review Committee (IRC) Based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessments

    Per protocol, the final analysis of PFS was to be performed after observing 142 PFS events in the pembrolizumab treatment arm. PFS was not assessed due to insufficient data collected.

    Time frame: Up to 32 months

Secondary outcomes

  1. Overall Survival (OS)

    Per protocol, if the final analysis of PFS was statistically significant for both cemiplimab combination therapy versus pembrolizumab treatment, the analysis of OS for cemiplimab combinations-versus-pembrolizumab comparison was to be performed at the time of PFS analysis, 12 months, and 18 months after analysis of PFS using the same method as used in the analysis of PFS.

    Time frame: Up to 32 months

  2. Objective Response Rate (ORR)

    Per protocol, the ORR for each cemiplimab combination-versus-pembrolizumab comparison was to be analyzed using the Cochran-Mantel-Haenszel test stratified by histological status (non-squamous versus squamous).

    Time frame: Up to 32 months

  3. Number of Treatment-Emergent Adverse Events (TEAEs)

    Time frame: Up to 32 months

  4. Number of Participants With Dose-Limiting Toxicities (DLTs)

    Time frame: Up to 32 months

  5. Number of Participants With Any Serious TEAEs

    Time frame: Up to 32 months

  6. Number of Participants With TEAEs Leading to Death

    Time frame: Up to 32 months

  7. Number of Participants With Laboratory Abnormalities

    Time frame: Up to 32 months

  8. Overall Survival (OS) at 12 Months

    Per protocol, if the final analysis of PFS was statistically significant for both cemiplimab combination therapy versus pembrolizumab treatment, the analysis of OS for cemiplimab combinations-versus-pembrolizumab comparison was to be performed at the time of PFS analysis, 12 months, and 18 months after analysis of PFS using the same method as used in the analysis of PFS.

    Time frame: At 12 months

  9. Overall Survival (OS) at 18 Months

    Per protocol, if the final analysis of PFS was statistically significant for both cemiplimab combination therapy versus pembrolizumab treatment, the analysis of OS for cemiplimab combinations-versus-pembrolizumab comparison was to be performed at the time of PFS analysis, 12 months, and 18 months after analysis of PFS using the same method as used in the analysis of PFS.

    Time frame: At 18 months

  10. Quality of Life (Core 30 Questionnaire)

    Quality of Life (QoL) as measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) four-point scale, with 1 as "not at all" and 4 as "very much." Per protocol, the change in EORTC QLQ-C30 scores from the first assessment to the end of the study were to be summarized descriptively at each post-baseline time point and compared using a mixed effects model, if appropriate.

    Time frame: Up to 32 months

  11. Quality of Life (Lung Cancer 13 Questionnaire)

    QoL as measured by the Quality of Life Questionnaire Lung Cancer 13 (EORTC QLQ-LC13) to assess lung cancer-associated symptoms and treatment-related side effects among lung cancer patients. The scale for EORTC-QLQ-LC13 is 1-4 for most outcome measures of systems, with 1 rated as "not at all" and 4 rated as "very much." Per protocol, the change in EORTC QLQ-LC13 scores from the first assessment to the end of the study were to be summarized descriptively at each post-baseline time point and compared using a mixed effects model, if appropriate.

    Time frame: Up to 32 months

07

Results

Posted Nov 16, 2022

Participant flow

This study was conducted at 3 centers that randomized 5 participants in the United States, Lithuania, and Italy.

Participant flow — Overall Study
MilestonePembrolizumabCemiplimab 350 mg Q3W + Ipilimumab 50 mg Q6WCemiplimab 350 mg Q3W + Chemotherapy + Ipilimumab 50 mg Q6W
Started032
Completed011
Not completed021
Withdrew: Death011
Withdrew: Progressive disease010

Outcome measures

PrimaryProgression-Free Survival (PFS) as Assessed by a Blinded Independent Review Committee (IRC) Based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessments

Per protocol, the final analysis of PFS was to be performed after observing 142 PFS events in the pembrolizumab treatment arm. PFS was not assessed due to insufficient data collected.

Time frame:
Up to 32 months

No measurements were reported for this outcome.

SecondaryOverall Survival (OS)

Per protocol, if the final analysis of PFS was statistically significant for both cemiplimab combination therapy versus pembrolizumab treatment, the analysis of OS for cemiplimab combinations-versus-pembrolizumab comparison was to be performed at the time of PFS analysis, 12 months, and 18 months after analysis of PFS using the same method as used in the analysis of PFS.

Time frame:
Up to 32 months

No measurements were reported for this outcome.

SecondaryObjective Response Rate (ORR)

Per protocol, the ORR for each cemiplimab combination-versus-pembrolizumab comparison was to be analyzed using the Cochran-Mantel-Haenszel test stratified by histological status (non-squamous versus squamous).

Time frame:
Up to 32 months

No measurements were reported for this outcome.

SecondaryNumber of Treatment-Emergent Adverse Events (TEAEs)
Time frame:
Up to 32 months
Reported as:
Number · Events
Number of Treatment-Emergent Adverse Events (TEAEs)
EventsCemiplimab 350 mg Q3W + Ipilimumab 50 mg Q6WCemiplimab 350 mg Q3W + Chemotherapy + Ipilimumab 50 mg Q6W
Number of Treatment-Emergent Adverse Events (TEAEs)6891
SecondaryNumber of Participants With Dose-Limiting Toxicities (DLTs)
Time frame:
Up to 32 months
Reported as:
Count of participants · Participants
Number of Participants With Dose-Limiting Toxicities (DLTs)
ParticipantsCemiplimab 350 mg Q3W + Ipilimumab 50 mg Q6WCemiplimab 350 mg Q3W + Chemotherapy + Ipilimumab 50 mg Q6W
Number of Participants With Dose-Limiting Toxicities (DLTs)00
SecondaryNumber of Participants With Any Serious TEAEs
Time frame:
Up to 32 months
Reported as:
Count of participants · Participants
Number of Participants With Any Serious TEAEs
ParticipantsCemiplimab 350 mg Q3W + Ipilimumab 50 mg Q6WCemiplimab 350 mg Q3W + Chemotherapy + Ipilimumab 50 mg Q6W
Number of Participants With Any Serious TEAEs22
SecondaryNumber of Participants With TEAEs Leading to Death
Time frame:
Up to 32 months
Reported as:
Count of participants · Participants
Number of Participants With TEAEs Leading to Death
ParticipantsCemiplimab 350 mg Q3W + Ipilimumab 50 mg Q6WCemiplimab 350 mg Q3W + Chemotherapy + Ipilimumab 50 mg Q6W
Number of Participants With TEAEs Leading to Death10
SecondaryNumber of Participants With Laboratory Abnormalities
Time frame:
Up to 32 months
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Abnormalities
ParticipantsCemiplimab 350 mg Q3W + Ipilimumab 50 mg Q6WCemiplimab 350 mg Q3W + Chemotherapy + Ipilimumab 50 mg Q6W
Number of Participants With Laboratory Abnormalities11
SecondaryOverall Survival (OS) at 12 Months

Per protocol, if the final analysis of PFS was statistically significant for both cemiplimab combination therapy versus pembrolizumab treatment, the analysis of OS for cemiplimab combinations-versus-pembrolizumab comparison was to be performed at the time of PFS analysis, 12 months, and 18 months after analysis of PFS using the same method as used in the analysis of PFS.

Time frame:
At 12 months

No measurements were reported for this outcome.

SecondaryOverall Survival (OS) at 18 Months

Per protocol, if the final analysis of PFS was statistically significant for both cemiplimab combination therapy versus pembrolizumab treatment, the analysis of OS for cemiplimab combinations-versus-pembrolizumab comparison was to be performed at the time of PFS analysis, 12 months, and 18 months after analysis of PFS using the same method as used in the analysis of PFS.

Time frame:
At 18 months

No measurements were reported for this outcome.

SecondaryQuality of Life (Core 30 Questionnaire)

Quality of Life (QoL) as measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) four-point scale, with 1 as "not at all" and 4 as "very much." Per protocol, the change in EORTC QLQ-C30 scores from the first assessment to the end of the study were to be summarized descriptively at each post-baseline time point and compared using a mixed effects model, if appropriate.

Time frame:
Up to 32 months
Reported as:
Mean · Score on a scale
Quality of Life (Core 30 Questionnaire)
Score on a scaleCemiplimab 350 mg Q3W + Ipilimumab 50 mg Q6WCemiplimab 350 mg Q3W + Chemotherapy + Ipilimumab 50 mg Q6W
Quality of Life (Core 30 Questionnaire)NA ± NANA ± NA
SecondaryQuality of Life (Lung Cancer 13 Questionnaire)

QoL as measured by the Quality of Life Questionnaire Lung Cancer 13 (EORTC QLQ-LC13) to assess lung cancer-associated symptoms and treatment-related side effects among lung cancer patients. The scale for EORTC-QLQ-LC13 is 1-4 for most outcome measures of systems, with 1 rated as "not at all" and 4 rated as "very much." Per protocol, the change in EORTC QLQ-LC13 scores from the first assessment to the end of the study were to be summarized descriptively at each post-baseline time point and compared using a mixed effects model, if appropriate.

Time frame:
Up to 32 months
Reported as:
Median · Score on a scale
Quality of Life (Lung Cancer 13 Questionnaire)
Score on a scaleCemiplimab 350 mg Q3W + Ipilimumab 50 mg Q6WCemiplimab 350 mg Q3W + Chemotherapy + Ipilimumab 50 mg Q6W
Quality of Life (Lung Cancer 13 Questionnaire)NA ± NANA ± NA

Adverse events

Collected over From first dose of study drug to end of study (up to 32 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cemiplimab 350 mg Q3W + Ipilimumab 50 mg Q6W2/3 (66.7%)2/3 (66.7%)3/3 (100%)
Cemiplimab 350 mg Q3W + Chemotherapy + Ipilimumab 50 mg Q6W1/2 (50%)2/2 (100%)2/2 (100%)
Most frequent serious events
Most frequent serious events
EventCemiplimab 350 mg Q3W + Ipilimumab 50 mg Q6WCemiplimab 350 mg Q3W + Chemotherapy + Ipilimumab 50 mg Q6W
PericarditisCardiac disorders0/31/2
HyponatraemiaMetabolism and nutrition disorders0/31/2
Secondary adrenocortical insufficiencyEndocrine disorders1/30/2
EnterocolitisGastrointestinal disorders1/30/2
GastritisGastrointestinal disorders1/30/2
Multiple organ dysfunction syndromeGeneral disorders1/30/2
Cytokine release syndromeImmune system disorders1/30/2
Back painMusculoskeletal and connective tissue disorders1/30/2
Most frequent other events
Showing 10 of 79
Most frequent other events
EventCemiplimab 350 mg Q3W + Ipilimumab 50 mg Q6WCemiplimab 350 mg Q3W + Chemotherapy + Ipilimumab 50 mg Q6W
AnaemiaBlood and lymphatic system disorders0/32/2
LeukopeniaBlood and lymphatic system disorders0/32/2
Abdominal pain upperGastrointestinal disorders1/32/2
NauseaGastrointestinal disorders1/32/2
Chest painGeneral disorders0/32/2
FatigueGeneral disorders2/32/2
FallInjury, poisoning and procedural complications0/32/2
Decreased appetiteMetabolism and nutrition disorders1/32/2
HypokalaemiaMetabolism and nutrition disorders1/32/2
Musculoskeletal chest painMusculoskeletal and connective tissue disorders0/32/2

Baseline characteristics

Safety analysis set (SAF), defined as all enrolled participants who received any amount of study treatment.

Age, Continuous
Age, Continuous(Years)Cemiplimab 350 mg Q3W + Ipilimumab 50 mg Q6WCemiplimab 350 mg Q3W + Chemotherapy + Ipilimumab 50 mg Q6WTotal
Mean61.7 ± 9.2956.5 ± 4.9559.6 ± 7.57
Sex: Female, Male
Sex: Female, Male(Participants)Cemiplimab 350 mg Q3W + Ipilimumab 50 mg Q6WCemiplimab 350 mg Q3W + Chemotherapy + Ipilimumab 50 mg Q6WTotal
Female303
Male022
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cemiplimab 350 mg Q3W + Ipilimumab 50 mg Q6WCemiplimab 350 mg Q3W + Chemotherapy + Ipilimumab 50 mg Q6WTotal
Hispanic or Latino000
Not Hispanic or Latino325
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cemiplimab 350 mg Q3W + Ipilimumab 50 mg Q6WCemiplimab 350 mg Q3W + Chemotherapy + Ipilimumab 50 mg Q6WTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White325
More than one race000
Unknown or Not Reported000
08

Study locations

3 sites
  • Regeneron Research Site
    Saint Petersburg, Florida 33709, United States
  • Regeneron Research Site
    Cremona, 26100, Italy
  • Regeneron Research Site
    Vilnius, 08660, Lithuania
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2018 to primary completion in Jul 2021, 36 months.

Results were first posted in Nov 2022, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2018
First posted
May 3, 2018
StartActual
Jul 2, 2018
Primary completionActual
Jul 29, 2021
CompletionActual
Jul 29, 2021
Results first posted
Nov 16, 2022
Last update
Nov 16, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 16, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03515629
Collaborators
Sanofi
Responsible party
Sponsor
First posted
May 3, 2018
Start date
Jul 2, 2018
Primary completion
Jul 29, 2021
Completion
Jul 29, 2021
Results posted
Nov 16, 2022
Last update
Nov 16, 2022

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cemiplimab

Start the discussion